From the Editor-in-Chief’s Desk: Harnessing Pharmacoepidemiology to Provide a Brighter Future for Children with Psychiatric Disorders

Abstract

Get full access to this article

View all access options for this article.

References

Amitai

, Etedgi

, Mevorach

, et al. A discrepancy in the reports on life events between parents and their depressed children is associated with lower responsiveness to SSRI treatment. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0039

Berloffa

, Masi

, Falcone

, et al. Clozapine treatment for aggressive behaviors in youths with neurodevelopmental disorders. J Child Adolesc Psychopharmacol, 2024; 34(3):148–156; doi: 10.1089/cap.2023.0097

Bobo

, Cooper

, Stein

, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry, 2013; 70(10):1067–1075; doi: 10.1001/jamapsychiatry.2013.2053

Bobo

. Not too rare to matter: The incidence of neuroleptic malignant syndrome in children and adolescents treated with antipsychotics. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0083

Farhat

, Behling

, Landeros-Weisenberger

, et al. pharmacological interventions for attention-deficit/hyperactivity disorder in children and adolescents with tourette disorder: A systematic review and network meta-analysis. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0049

Lee

, Amill-Rosario

, Reeves

, et al. Incident psychotropic medication use among US commercially insured children and adolescents from 2019 to 2022. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0035

Pimenta de Figueiredo

, de Almeida

, de Freitas

FAC

, et al. Beyond the Off-Label: A systematic review of what we know about clozapine use for children. J Child Adolesc Psychopharmacol, 2024; doi: 10.1089/cap.2024.0070

Radecki

, Robieson

, Gopalkrishnan

, et al. Safety and efficacy of levomilnacipran extended release in pediatric patients aged 7–17 years with major depressive disorder: Results of two phase 3, randomized, double-blind studies. J Child Adolesc Psychopharmacol, 2024; 34(5):241–250; doi: 10.1089/cap.2023.0080

Ray

, Fuchs

, Olfson

, et al. Incidence of neuroleptic malignant syndrome during antipsychotic treatment in children and youth: A national cohort study. J Child Adolesc Psychopharmacol, 2024a; doi: 10.1089/cap.2024.0047

10.

Ray

, Fuchs

, Olfson

, et al. Antipsychotic medications and mortality in children and young adults. JAMA Psychiatry, 2024b;81(3):260–269; doi: 10.1001/jamapsychiatry.2023.4573